Pre-exposure prophylaxis (PrEP) For Human Immunodeficiency Virus (HIV)? Yes or No  NSG 502:

         Pre-exposure prophylaxis (PrEP) For Human Immunodeficiency Virus (HIV)? Yes or No  NSG 502:  Advanced Nursing ResearchWilkes University, Passan School of NursingDue: February 6, 2022                        Pre-exposure prophylaxis (PrEP) For Human Immunodeficiency Virus (HIV)? Yes or No In 2017, the Centers for Disease Control and Prevention (CDC) recommended Pre-exposure prophylaxis (PrEP). PrEP is prescribed for individuals who are negative for the Human Immunodeficiency Virus (HIV).  PrEP is a combination of antiretroviral medications that works to prevent the virus from establishing a permanent infection in the body (Aaron et al., 2018). PrEP involves the use of condoms and a follow-up with a healthcare provider every three months for testing. Studies have proved when taken as prescribed Pre-exposure prophylaxis (PrEP) PrEp has likely contributed to a substantial decline in the HIV epidemic (Aaron et al., 2018). Background and Significance[SDK1] The Human Immunodeficiency Virus (HIV) is a retrovirus that attacks an individuals’ immune system. If untreated HIV can lead to AIDS (acquired immunodeficiency syndrome). Currently, there is no cure for this virus. Researchers believe HIV may began as far back as the late 1800s transferred from chimpanzees to humans. HIV has slowly spread from the continent of Africa throughout the world. The virus was introduced in America in the late 1970s (MacGibbon et al., 2021).Currently, over 36 million people worldwide have HIV. In 2016, there were 2.10 million new HIV infections and 1.80 million AIDS-related deaths. UNAIDS predicts this for 2016. In Sub-Saharan Africa, roughly one-quarter of the population is HIV-positive Spinner, Pre-exposure prophylaxis (PrEP) is one of the most promising HIV prevention strategies. Studies show PrEP is highly effective in preventing HIV infection in high-risk populations, including heterosexual couples with one HIV-positive partner and the other not. In conclusion, many concerns remain unanswered about how to best implement PrEP programs, including who should be provided PrEP and how often. This paper will examine the feasibility and effectiveness of PrEP in high-risk groups. The purpose is to teach policymakers and healthcare practitioners on how to best use PrEP to prevent HIV infection. Individuals with HIV comprise a good portion of the United States population. They have been discriminated against and antagonized against before they even are aware of their status. However, with newer medications and interventions many still refuse the necessary assistance in lowering their risk of the conquering this disease.Problem Statement            The problem addressed in this proposal is if human immunodeficiency virus (HIV) continues to be an epidemic, why aren’t more individuals not taking PrEP?  Purpose Statement            The purpose of this proposal is to investigate the feasibility and effectiveness of PrEP as a means of preventing HIV infection in high-risk populations. PICOT Question                         The PICOT question is. Are males 30-45 (P) who don’t take pre-exposure prophylaxis (PrEP) (I) compared with those taking PrEP (C) at an increased risk (O) for human immunodeficiency virus (HIV) after three months of treatment (T)?  Conclusion            In conclusion, many concerns remain unanswered about how to best implement PrEP programs, including who should be provided PrEP and how often. This paper will examine the feasibility and effectiveness of PrEP in high-risk groups. The purpose is to teach policymakers and healthcare practitioners on how to best use PrEP to prevent HIV infection. Individuals with HIV comprise a good portion of the United States population. They have been discriminated against and antagonized against before they even are aware of their status. However, with newer medications and interventions many still refuse the necessary assistance in lowering their risk of the conquering this disease.              References Aaron, E., Blum, C., Seidman, D., Hoyt, M. J., Simone, J., Sullivan, M., & Smith, D. K. (2018). Optimizing delivery of HIV preexposure prophylaxis for women in the United States. AIDS patient care and STDs, 32(1), 16-23. https://doi.org/10.1089/apc.2017.0201 Baugher, A. R., Trujillo, L., Kanny, D., Freeman, J. Q., Hickey, T., Sionean, C., … & National HIV Behavioral Surveillance Study Group. (2021). Racial, Ethnic, and Gender Disparities in Awareness of Preexposure Prophylaxis Among HIV-Negative Heterosexually Active Adults at Increased Risk for HIV Infection—23 Urban Areas, United States, 2019. Morbidity and Mortality Weekly Report, 70(47), 1635. https://doi.10.15585/mmwr.mm7047a3 MacGibbon, J., Lea, T., Ellard, J., Murphy, D., Kolstee, J., Power, C., … & Holt, M. (2021). Access to subsidized health care affects HIV Pre-Exposure Prophylaxis (PrEP) uptake among gay and bisexual men in Australia: results of National Surveys 2013-2019. JAIDS Journal of Acquired Immune Deficiency Syndromes, 86(4), 430-435.https:// doi: 10.1097/QAI.0000000000002572    [SDK1]It is possible you will need to organize this section with more headings.  If that is the case, the headings will be flush with the left margin and bolded. Health Science Science Nursing NURSING 502 Share QuestionEmailCopy link Comments (0)

Having Trouble Meeting Your Deadline?

Get your assignment on          Pre-exposure prophylaxis (PrEP) For Human Immunodeficiency Virus (HIV)? Yes or No  NSG 502: completed on time. avoid delay and – ORDER NOW

Do My Paper

Our website has a team of professional writers who can help you write any of your homework. They will write your papers from scratch. We also have a team of editors just to make sure all papers are of HIGH QUALITY & PLAGIARISM FREE. To make an Order you only need to click Order Now and we will direct you to our Order Page at Litessays. Then fill Our Order Form with all your assignment instructions. Select your deadline and pay for your paper. You will get it few hours before your set deadline.